A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by activating the mother’s immune system to produce defence proteins, which are then passed to the foetus through the placenta. This maternal immunity provides newborns with instant defence from the point of delivery, exactly when they are highly susceptible to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide meaningful protection, with evidence suggesting that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson advises pregnant women to have the vaccine on schedule, whilst observing that protection can still occur even if administered later in the third trimester.
- Nearly 85 per cent coverage when immunised four weeks before birth
- Maternal antibodies passed through placenta protect newborns from day one
- Protection achievable with 2-week gap before premature birth
- Vaccination during the third trimester still provides significant infant protection
Compelling evidence from the latest research
The effectiveness of the pregnancy RSV vaccine has been demonstrated through a thorough investigation conducted across England, examining data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately 90% of all births during that half-year window, providing strong and reliable data of the vaccine’s real-world impact. The study’s conclusions have been endorsed by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The scale of this research gives healthcare professionals and prospective parents with trust in the vaccine’s established performance across diverse populations and circumstances.
The results present a striking picture of the vaccine’s ability to protect. More than 4,500 babies were treated in hospital with RSV during the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This marked difference highlights the vaccine’s critical role in reducing the risk of serious illness in newborns. The drop in hospital admissions exceeding 80 per cent represents a substantial public health milestone, helping to prevent thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings reinforce the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research reviewed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection levels and hospital admissions. The substantial sample size and comprehensive nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than isolated cases or limited subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to establish the shortest interval needed between vaccination and birth for maximum protection, as well as to determine whether protection stayed significant with briefer timeframes. The methodology captured real-world outcomes rather than laboratory-based settings, providing real-world data of how the vaccine functions when given across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the risks
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection causes deep inflammation in the lungs and airways, making it perilously hard for infected babies to breathe and feed effectively. Parents often witness their babies visibly struggling, their chests heaving as they attempt to draw enough air into their weakened respiratory system. Whilst the majority of babies recover with palliative treatment, a small but significant proportion perish from respiratory syncytial virus complications each year, making prevention through vaccination a vital health service objective for safeguarding the youngest and most at-risk members of society.
- RSV causes inflammation in lungs, resulting in serious respiratory problems in babies
- Nearly 50% of newborns acquire the infection during their first few months alive
- Symptoms range from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK infants need serious hospital treatment for RSV annually
- Few babies succumb to RSV related complications annually in the UK
Take-up rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have stressed the importance of pregnant women getting their jab at the ideal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that timing matters greatly for ensuring newborns receive the most robust immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery provides approximately 85% protection, experts advise women to receive their vaccine as early as possible from 28 weeks of pregnancy onwards to enhance the antibodies transferred to their babies through the placenta.
The communication from health authorities stays clear: pregnant women ought to prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has provided reassurance to pregnant women that protection is still achievable with shorter intervals between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach acknowledges the practical demands of pregnancy whilst maintaining strong protection for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional disparities in immunisation
Whilst the RSV vaccine programme has been rolled out across England, uptake rates and implementation timelines have differed across various areas and NHS trusts. Some areas have attained higher vaccination coverage among qualifying expectant mothers, whilst others continue working to increase awareness and availability of the jab. These regional differences reflect differences across medical facilities, engagement approaches, and community involvement initiatives, though the overall statistics shows consistently strong protection regardless of geographical location.
- NHS trusts deploying varied communication campaigns to reach pregnant women
- Geographic variations in vaccination coverage levels across England necessitate strategic intervention
- Regional health providers adapting programmes to meet local requirements and situations
Real-world impact and parental perspectives
The vaccine’s impressive effectiveness translates into tangible benefits for families throughout the United Kingdom. With more than 20,000 babies hospitalised annually due to RSV prior to the launch of this safeguarding intervention, the 80% reduction in admissions represents thousands of infants protected against severe infection. Parents no longer face the upsetting situation of watching their newborns labour to breathe or struggle to eat, symptoms that characterise critical RSV illness. The vaccine has fundamentally shifted the terrain of neonatal breathing health, offering expectant mothers a preventative option to shield their most at-risk babies during those crucial first weeks.
For families like that of Malachi, whose serious RSV infection resulted in severe brain damage, the vaccine’s accessibility carries deep personal significance. His mother’s support of the jab underscores the life-altering consequences that preventable illness can inflict on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now given protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to women in pregnancy during their final trimester, changing what was once an inevitable seasonal threat into a manageable risk.